About the Company
Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Albireo's lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 pivotal trials in PFIC, Alagille syndrome and biliary atresia. The Company completed IND-enabling studies for new preclinical candidate A3907 this year and plans to advance development in adult liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ALBO News
ALBIREO PHARMA INC COM Stock (NASDAQ:ALBO), Dividends
ALBIREO PHARMA INC COM issues dividends to shareholders from excess cash ALBIREO PHARMA INC COM generates. Most companies pay dividends on a quarterly basis, but dividends may also be paid monthly ...
Analyst Ratings for Albireo Pharma
These 5 analysts have an average price target of $43.2 versus the current price of Albireo Pharma at $44.29, implying downside. Below is a summary of how these 5 analysts rated Albireo Pharma over ...
Albireo Pharma Inc.
Albireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver ...
ALBIREO PHARMA INC COM Stock (NASDAQ:ALBO), Short Interest Report
Short interest for ALBIREO PHARMA INC COM gives investors a sense of the degree to which investors are betting on the decline of ALBIREO PHARMA INC COM's stock. Short interest data is updated ...
Albireo Gets FDA Priority Review of Bylvay in Alagille Syndrome >ALBO
Albireo Pharma Inc. on Tuesday said the U.S. Food and Drug Administration granted priority review to its application seeking expanded approval of its Bylvay drug for patients with the rare liver ...
Albireo Pharma, Inc. Common Stock (ALBO)
Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result, these ...
Albireo Pharma
Leveraging Big Data multi-factor models, the Q-Factor Score is assigned to each stock ranging from “Top Buy” to “Top Short”. The Q-Factor Score represents an expectation for how a stock ...
Albireo Pharma, Inc. Common Stock (ALBO)
Get up to 10 years of daily historical stock prices & volumes. Data provided by Edgar Online. ©2021, EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally ...
Albireo Pharma, Inc. (ALBO)
CinCor Pharma (NASDAQ: CINC) is being bought out by deep-pocketed pharmaceutical company AstraZeneca, while Albireo Pharma (NASDAQ: ALBO) is set to be owned by France-based peer Ipsen. Both of these ...
Loading the latest forecasts...